Following this activity, participants should be able to: (1) Personalize locoregional treatment planning based on tumor biology and patient factors. (2) Summarize evolving radiation therapy techniques and their impact on treatment efficacy and toxicity. (3) Explain the selection criteria of adjuvant systemic therapies including CDK4/6 inhibitors for HR-positive early-stage breast cancer. (4) Select and sequence systemic therapy for triple negative early-stage breast cancer.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Free CME Activity | Free |
| Paid Activity (e.g. Breast/Lung Cancer Congress recordings) | $50 |
| Paid Activity (e.g. Hematologic Malignancies Congress recording) | $90 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Anatomic & Clinical Pathology
- Colon & Rectal Surgery
- Communication & Shared Decision-Making
- Dermatopathology
- Evidence-Based Medicine & Research
- Gastroenterology
- Gastrointestinal Surgery
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Nephrology
- Neurology
- Obstetrics & Gynecology
- Pain Medicine
- Pediatric Hematology-Oncology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Primary care
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
- On-demand / recorded video
- Credit · Up to 1.75 credits
- MOC · Up to 1.75 points
- Paid · this provider typically $50
- Commercial Support
-
ReleasedJun 15, 2026
-
Last day to claim creditMar 2, 2027 5 months left
-
PRIME Education, Inc. (PRIME®) Personalizing Adjuvant Therapy in HR+/HER2- Early-Stage Breast Cancer Based on Latest Evidence and Patient-Specific Factors
-
Clinical Care Options, LLC (dba Decera Clinical Education) Personalizing Treatment for Early-Stage Breast Cancer: Where We Are and Where We Are Headed
-
Living Beyond Breast Cancer +1 Key Steps to Success With CDK4/6 Inhibition in Early Through Metastatic Breast Cancer: Stratification, Selection, Sequencing, and Specialty Management
-
National Comprehensive Cancer Network Team Strategies for Overcoming Challenges to Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer
-
National Comprehensive Cancer Network Case Challenge: Optimizing Adjuvant Therapy for a 39-Year-Old Premenopausal Woman With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
-
National Comprehensive Cancer Network Recorded Presentation from the NCCN 2026 Annual Conference: Non-Small Cell Lung Cancer Case Review
